Published in AJR Am J Roentgenol on August 01, 2007
MRI Guided Transurethral HIFU for Various Prostate Diseases (HIFU-PRO) | NCT03350529
Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. JAMA (2015) 9.02
ESUR prostate MR guidelines 2012. Eur Radiol (2012) 8.86
Advancements in MR imaging of the prostate: from diagnosis to interventions. Radiographics (2011) 2.17
Diffusion-weighted endorectal MR imaging at 3 T for prostate cancer: tumor detection and assessment of aggressiveness. Radiology (2011) 2.10
Clinical application of a 3D ultrasound-guided prostate biopsy system. Urol Oncol (2011) 2.03
Imaging techniques for prostate cancer: implications for focal therapy. Nat Rev Urol (2009) 1.76
Multiparametric magnetic resonance imaging findings in men with low-risk prostate cancer followed using active surveillance. BJU Int (2013) 1.55
Prostate tumor volume measurement with combined T2-weighted imaging and diffusion-weighted MR: correlation with pathologic tumor volume. Radiology (2009) 1.55
Optimization of prostate biopsy: the role of magnetic resonance imaging targeted biopsy in detection, localization and risk assessment. J Urol (2014) 1.55
Elastic registration of multimodal prostate MRI and histology via multiattribute combined mutual information. Med Phys (2011) 1.54
Multiparametric MRI of prostate cancer: an update on state-of-the-art techniques and their performance in detecting and localizing prostate cancer. J Magn Reson Imaging (2013) 1.54
A method for correlating in vivo prostate magnetic resonance imaging and histopathology using individualized magnetic resonance-based molds. Rev Sci Instrum (2009) 1.42
Ultra-high-b-value diffusion-weighted MR imaging for the detection of prostate cancer: evaluation in 201 cases with histopathological correlation. Eur Radiol (2010) 1.40
Diffusion-weighted magnetic resonance imaging for the evaluation of prostate cancer: optimal B value at 3T. Korean J Radiol (2012) 1.33
Diffusion-weighted MRI in the detection of prostate cancer: meta-analysis. AJR Am J Roentgenol (2012) 1.28
Correlation of Gleason scores with diffusion-weighted imaging findings of prostate cancer. Adv Urol (2011) 1.25
Carr-Purcell-Meiboom-Gill imaging of prostate cancer: quantitative T2 values for cancer discrimination. Magn Reson Imaging (2008) 1.13
Imaging prostate cancer: an update on positron emission tomography and magnetic resonance imaging. Curr Urol Rep (2010) 1.11
Prediction of prostate cancer extracapsular extension with high spatial resolution dynamic contrast-enhanced 3-T MRI. Eur Radiol (2012) 1.11
Multiparametric magnetic resonance imaging of prostate cancer. Indian J Radiol Imaging (2012) 1.09
Multidisciplinary functional MR imaging for prostate cancer. Korean J Radiol (2009) 1.04
Current approaches, challenges and future directions for monitoring treatment response in prostate cancer. J Cancer (2014) 1.04
Dynamic contrast-enhanced MRI of anterior prostate cancer: morphometric assessment and correlation with radical prostatectomy findings. Eur Radiol (2008) 1.02
Simultaneous hyperpolarized (13)C-pyruvate MRI and (18)F-FDG-PET in cancer (hyperPET): feasibility of a new imaging concept using a clinical PET/MRI scanner. Am J Nucl Med Mol Imaging (2014) 1.02
Automated prostate cancer detection via comprehensive multi-parametric magnetic resonance imaging texture feature models. BMC Med Imaging (2015) 1.02
Focal therapy in prostate cancer: modalities, findings and future considerations. Nat Rev Urol (2010) 1.00
The emerging role of diffusion-weighted MRI in prostate cancer management. Nat Rev Urol (2012) 0.99
Decision support system for localizing prostate cancer based on multiparametric magnetic resonance imaging. Med Phys (2012) 0.96
Diffusion weighted imaging in prostate cancer. Eur Radiol (2010) 0.95
Prospective comparison of T2w-MRI and dynamic-contrast-enhanced MRI, 3D-MR spectroscopic imaging or diffusion-weighted MRI in repeat TRUS-guided biopsies. Eur Radiol (2010) 0.94
The role of magnetic resonance imaging (MRI) in focal therapy for prostate cancer: recommendations from a consensus panel. BJU Int (2013) 0.94
Biopsy needle artifact localization in MRI-guided robotic transrectal prostate intervention. IEEE Trans Biomed Eng (2012) 0.93
Diffusion weighted magnetic resonance imaging and its recent trend-a survey. Quant Imaging Med Surg (2015) 0.93
Magnetic resonance image guided brachytherapy. Semin Radiat Oncol (2014) 0.92
Multiparametric magnetic resonance imaging of the prostate: current concepts. Radiol Bras (2015) 0.92
Prostate Biopsy Using Transrectal Ultrasonography; The Optimal Number of Cores Regarding Cancer Detection Rate and Complications. Iran J Radiol (2015) 0.92
Reducing the influence of b-value selection on diffusion-weighted imaging of the prostate: evaluation of a revised monoexponential model within a clinical setting. J Magn Reson Imaging (2011) 0.92
Diagnostic value of ADC in patients with prostate cancer: influence of the choice of b values. Eur Radiol (2012) 0.91
Focal therapy in the management of prostate cancer: an emerging approach for localized prostate cancer. Adv Urol (2012) 0.91
Predicting post-external beam radiation therapy PSA relapse of prostate cancer using pretreatment MRI. Int J Radiat Oncol Biol Phys (2010) 0.90
Correlated diffusion imaging. BMC Med Imaging (2013) 0.90
Seminal vesicle invasion in prostate cancer: prediction with combined T2-weighted and diffusion-weighted MR imaging. Eur Radiol (2009) 0.89
Extracelluar matrix metalloproteinase as a novel target for pancreatic cancer therapy. Anticancer Drugs (2011) 0.89
The current and future role of magnetic resonance imaging in prostate cancer detection and management. Transl Androl Urol (2015) 0.89
Detectability of low and intermediate or high risk prostate cancer with combined T2-weighted and diffusion-weighted MRI. Eur Radiol (2012) 0.88
MRI for men undergoing active surveillance or with rising PSA and negative biopsies. Nat Rev Urol (2010) 0.88
Preoperative mp-MRI of the prostate provides little information about staging of prostate carcinoma in daily clinical practice. World J Urol (2014) 0.87
Combined prostate diffusion tensor imaging and dynamic contrast enhanced MRI at 3T--quantitative correlation with biopsy. Magn Reson Imaging (2010) 0.86
The optimal timing of post-prostate biopsy magnetic resonance imaging to guide nerve-sparing surgery. Asian J Androl (2014) 0.86
Incremental learning with SVM for multimodal classification of prostatic adenocarcinoma. PLoS One (2014) 0.86
Diffusion-weighted MR imaging in gynecologic cancers. J Gynecol Oncol (2011) 0.85
Multiparametric-MRI in diagnosis of prostate cancer. Indian J Urol (2015) 0.85
Innovations in diagnostic imaging of localized prostate cancer. World J Urol (2014) 0.84
Contrast-enhanced ultrasonography for real-time monitoring of interstitial laser thermal therapy in the focal treatment of prostate cancer. Can Urol Assoc J (2009) 0.84
Focal therapy for prostate cancer: revolution or evolution? BMC Urol (2009) 0.84
Prostate cancer discrimination in the peripheral zone with a reduced field-of-view T(2)-mapping MRI sequence. Magn Reson Imaging (2015) 0.84
Magnetic resonance-ultrasound fusion prostate biopsy in the diagnosis of prostate cancer. Urol Oncol (2016) 0.84
Diffusion-weighted magnetic resonance imaging in cancer: Reported apparent diffusion coefficients, in-vitro and in-vivo reproducibility. World J Radiol (2016) 0.84
Diffusion-weighted MRI of the prostate: advantages of Zoomed EPI with parallel-transmit-accelerated 2D-selective excitation imaging. Eur Radiol (2014) 0.83
3 Tesla multiparametric MRI for GTV-definition of Dominant Intraprostatic Lesions in patients with Prostate Cancer--an interobserver variability study. Radiat Oncol (2013) 0.83
Pitfalls and Limitations of Diffusion-Weighted Magnetic Resonance Imaging in the Diagnosis of Urinary Bladder Cancer. Transl Oncol (2015) 0.83
Functional and molecular imaging of localized and recurrent prostate cancer. Eur J Nucl Med Mol Imaging (2013) 0.83
Prostate diffusion imaging with distortion correction. Magn Reson Imaging (2015) 0.83
Image guidance for focal therapy of prostate cancer. World J Urol (2010) 0.83
Pathologic basis of focal therapy for early-stage prostate cancer. Nat Rev Urol (2009) 0.83
Functional MRI in prostate cancer detection. Biomed Res Int (2014) 0.83
A system for evaluating magnetic resonance imaging of prostate cancer using patient-specific 3D printed molds. Am J Clin Exp Urol (2014) 0.82
Technical Note: Method to correlate whole-specimen histopathology of radical prostatectomy with diagnostic MR imaging. Med Phys (2016) 0.81
Geometric distortion in diffusion-weighted MR imaging of the prostate-contributing factors and strategies for improvement. Acad Radiol (2014) 0.81
Role for (11)C-choline PET in active surveillance of prostate cancer. Can Urol Assoc J (2015) 0.81
Computed diffusion-weighted imaging of the prostate at 3 T: impact on image quality and tumour detection. Eur Radiol (2013) 0.81
Current role of multiparametric magnetic resonance imaging for prostate cancer. Quant Imaging Med Surg (2015) 0.80
Computer aided-diagnosis of prostate cancer on multiparametric MRI: a technical review of current research. Biomed Res Int (2014) 0.80
Prostatic ductal adenocarcinoma: an aggressive tumour variant unrecognized on T2 weighted magnetic resonance imaging (MRI). Eur Radiol (2014) 0.80
Magnetic resonance imaging for prostate cancer clinical application. Chin J Cancer Res (2013) 0.79
Diffusion-weighted MRI for detecting prostate tumour in men at increased genetic risk. Eur J Radiol Open (2016) 0.79
Recent advances in magnetic resonance imaging of prostate cancer. F1000 Med Rep (2010) 0.79
Relationship between T2 relaxation and apparent diffusion coefficient in malignant and non-malignant prostate regions and the effect of peripheral zone fractional volume. Br J Radiol (2013) 0.79
Transrectal real-time elastography-guided transperineal prostate biopsy as an improved tool for prostate cancer diagnosis. Int J Clin Exp Med (2015) 0.78
Early experience in MRI-guided therapies of prostate cancer: HIFU, laser and photodynamic treatment. Cancer Imaging (2011) 0.78
Benign causes of diffusion restriction foci in the peripheral zone of the prostate: diagnosis and differential diagnosis. Abdom Radiol (2016) 0.78
False positive and false negative diagnoses of prostate cancer at multi-parametric prostate MRI in active surveillance. Insights Imaging (2015) 0.77
Autonomous real-time interventional scan plane control with a 3-D shape-sensing needle. IEEE Trans Med Imaging (2014) 0.77
Nonvisible tumors on multiparametric magnetic resonance imaging does not predict low-risk prostate cancer. Prostate Int (2015) 0.77
DW-MRI of the urogenital tract: applications in oncology. Cancer Imaging (2010) 0.77
Multiparametric MRI for localized prostate cancer: lesion detection and staging. Biomed Res Int (2014) 0.77
Diffusion-weighted MR imaging for the differentiation of malignant from benign strictures in the periampullary region. Eur Radiol (2012) 0.77
PET/CT imaging of recurrent prostate cancer. Eur J Nucl Med Mol Imaging (2008) 0.77
The Clinical Value of Performing an MRI before Prostate Biopsy. Korean J Urol (2011) 0.76
The Utility of Diffusion Weighted Imaging (DWI) Using Apparent Diffusion Coefficient (ADC) Values in Discriminating Between Prostate Cancer and Normal Tissue. Pol J Radiol (2014) 0.76
Short-term reproducibility of apparent diffusion coefficient estimated from diffusion-weighted MRI of the prostate. Abdom Imaging (2015) 0.75
Role of serial multiparametric magnetic resonance imaging in prostate cancer active surveillance. World J Radiol (2016) 0.75
The accuracy of prostate cancer localization diagnosed on transrectal ultrasound-guided biopsy compared to 3-dimensional transperineal approach. Adv Urol (2013) 0.75
Restriction spectrum imaging: An evolving imaging biomarker in prostate MRI. J Magn Reson Imaging (2016) 0.75
MR elastography to measure the effects of cancer and pathology fixation on prostate biomechanics, and comparison with T 1, T 2 and ADC. Phys Med Biol (2017) 0.75
Trends in targeted prostate brachytherapy: from multiparametric MRI to nanomolecular radiosensitizers. Cancer Nanotechnol (2016) 0.75
Focus on diffusion MR investigations of musculoskeletal tissue to improve osteoporosis diagnosis: a brief practical review. Biomed Res Int (2015) 0.75
Magnetic resonance imaging detected prostate evasive anterior tumours: Further insights. Can Urol Assoc J (2015) 0.75
Value of T1/T2-weighted magnetic resonance imaging registration to reduce the postbiopsy hemorrhage effect for prostate cancer localization. Prostate Int (2015) 0.75
Defining the radiobiology of prostate cancer progression: An important question in translational prostate cancer research. Exp Biol Med (Maywood) (2014) 0.75
Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol (2010) 6.01
High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res (2005) 4.61
A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial. J Urol (2010) 3.79
Active surveillance of small renal masses: progression patterns of early stage kidney cancer. Eur Urol (2011) 3.75
Impact of 5α-reductase inhibitors on men followed by active surveillance for prostate cancer. Eur Urol (2010) 3.41
Validating whole slide imaging for diagnostic purposes in pathology: guideline from the College of American Pathologists Pathology and Laboratory Quality Center. Arch Pathol Lab Med (2013) 3.39
Review of the current state of whole slide imaging in pathology. J Pathol Inform (2011) 3.23
Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement. Neoplasia (2006) 3.08
Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol (2008) 3.02
Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol (2009) 2.78
The actual value of the surgical margin status as a predictor of disease progression in men with early prostate cancer. Eur Urol (2006) 2.71
Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. J Urol (2007) 2.69
Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol (2013) 2.53
The uncertainty of radio frequency treatment of renal cell carcinoma: findings at immediate and delayed nephrectomy. J Urol (2002) 2.48
Techniques, safety and accuracy of sampling of renal tumors by fine needle aspiration and core biopsy. J Urol (2007) 2.33
Change in diffusion weighted MRI during liver cancer radiotherapy: preliminary observations. Acta Oncol (2009) 2.33
The contemporary concept of significant versus insignificant prostate cancer. Eur Urol (2011) 2.29
Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias. Cancer Genet Cytogenet (2006) 2.23
Evidence for a biopsy derived grade artifact among larger prostate glands. J Urol (2006) 2.23
Prospective multi-institutional study evaluating the performance of prostate cancer risk calculators. J Clin Oncol (2011) 2.21
Variability in diagnostic opinion among pathologists for single small atypical foci in prostate biopsies. Am J Surg Pathol (2010) 2.16
Assessing individual risk for prostate cancer. J Clin Oncol (2007) 2.13
Association between germline HOXB13 G84E mutation and risk of prostate cancer. J Natl Cancer Inst (2012) 2.06
Regulation of endocytosis via the oxygen-sensing pathway. Nat Med (2009) 2.00
Inverse relationship between biochemical outcome and acute toxicity after image-guided radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys (2011) 2.00
High-level JAG1 mRNA and protein predict poor outcome in breast cancer. Mod Pathol (2007) 1.94
Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study. Eur Urol (2007) 1.89
Prostate cancer detection with multi-parametric MRI: logistic regression analysis of quantitative T2, diffusion-weighted imaging, and dynamic contrast-enhanced MRI. J Magn Reson Imaging (2009) 1.88
IMRT for adjuvant radiation in gastric cancer: a preferred plan? Int J Radiat Oncol Biol Phys (2005) 1.84
Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors. Hum Mol Genet (2004) 1.80
Tubular carcinoma of the breast: further evidence to support its excellent prognosis. J Clin Oncol (2009) 1.77
FGFR3 mutations and a normal CK20 staining pattern define low-grade noninvasive urothelial bladder tumours. Eur Urol (2007) 1.72
Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders. Eur J Hum Genet (2002) 1.72
A novel serum marker, total prostate secretory protein of 94 amino acids, improves prostate cancer detection and helps identify high grade cancers at diagnosis. J Urol (2006) 1.71
Do older men benefit from curative therapy of localized prostate cancer? J Clin Oncol (2003) 1.70
Activation of Notch signaling in human colon adenocarcinoma. Int J Oncol (2008) 1.66
Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy. Int J Radiat Oncol Biol Phys (2007) 1.66
Prostate volume is strongest predictor of cancer diagnosis at transrectal ultrasound-guided prostate biopsy with prostate-specific antigen values between 2.0 and 9.0 ng/mL. Urology (2007) 1.58
Solitary extramedullary plasmacytoma of the head and neck--long-term outcome analysis of 68 cases. Head Neck (2008) 1.56
Population based survival data on urachal tumors. J Urol (2006) 1.55
Postradiotherapy quality of life for head-and-neck cancer patients is independent of xerostomia. Int J Radiat Oncol Biol Phys (2005) 1.54
Pathological, oncologic and functional outcomes of radical prostatectomy following active surveillance. J Urol (2013) 1.54
Contemporary results of percutaneous biopsy of 100 small renal masses: a single center experience. J Urol (2008) 1.53
Prostate cancers scored as Gleason 6 on prostate biopsy are frequently Gleason 7 tumors at radical prostatectomy: implication on outcome. J Urol (2006) 1.53
Predictive value of tumor thickness for cervical lymph-node involvement in squamous cell carcinoma of the oral cavity: a meta-analysis of reported studies. Cancer (2009) 1.50
'Prostatic evasive anterior tumours': the role of magnetic resonance imaging. BJU Int (2009) 1.48
Audit of performance of needle core biopsy diagnoses of screen detected breast lesions. Eur J Cancer (2008) 1.48
Impact of multiparametric endorectal coil prostate magnetic resonance imaging on disease reclassification among active surveillance candidates: a prospective cohort study. J Urol (2012) 1.47
Conditional survival analyses across cancer sites. Health Rep (2011) 1.46
Measurement of peri-prostatic fat thickness using transrectal ultrasonography (TRUS): a new risk factor for prostate cancer. BJU Int (2012) 1.46
Median 5 year follow-up of 125iodine brachytherapy as monotherapy in men aged<or=55 years with favorable prostate cancer. Urology (2009) 1.45
Physical activity and quality of life after radical prostatectomy. Can Urol Assoc J (2010) 1.44
Large cell neuroendocrine carcinoma of prostate: a clinicopathologic summary of 7 cases of a rare manifestation of advanced prostate cancer. Am J Surg Pathol (2006) 1.42
Final report of multicenter Canadian Phase III randomized trial of 3 versus 8 months of neoadjuvant androgen deprivation therapy before conventional-dose radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys (2008) 1.41
Radical prostatectomy in obese patients: Improved surgical outcomes in recent years. Int J Urol (2010) 1.41
Utility of incorporating genetic variants for the early detection of prostate cancer. Clin Cancer Res (2009) 1.39
Personal digital assistant data capture: the future of quality of life measurement in prostate cancer treatment. J Oncol Pract (2007) 1.39
Treatment planning and dose analysis for interstitial photodynamic therapy of prostate cancer. Phys Med Biol (2009) 1.39
Prostate tissue composition and MR measurements: investigating the relationships between ADC, T2, K(trans), v(e), and corresponding histologic features. Radiology (2010) 1.36
Clinical predictors of Gleason score upgrading: implications for patients considering watchful waiting, active surveillance, or brachytherapy. Cancer (2007) 1.35
Influence of mammographic parenchymal pattern in screening-detected and interval invasive breast cancers on pathologic features, mammographic features, and patient survival. AJR Am J Roentgenol (2007) 1.34
Techniques for delivery and monitoring of TOOKAD (WST09)-mediated photodynamic therapy of the prostate: clinical experience and practicalities. J Photochem Photobiol B (2005) 1.34
Impact of positive surgical margins after radical prostatectomy differs by disease risk group. J Urol (2010) 1.33
Prevalence of prostate cancer on autopsy: cross-sectional study on unscreened Caucasian and Asian men. J Natl Cancer Inst (2013) 1.32
Epithelioid angiomyolipoma: a morphologically distinct variant that mimics a variety of intra-abdominal neoplasms. Arch Pathol Lab Med (2011) 1.31
Human HIF-3alpha4 is a dominant-negative regulator of HIF-1 and is down-regulated in renal cell carcinoma. FASEB J (2005) 1.30
Prostate gland: MR imaging appearance after vascular targeted photodynamic therapy with palladium-bacteriopheophorbide. Radiology (2007) 1.29
Inter- and intrafractional tumor and organ movement in patients with cervical cancer undergoing radiotherapy: a cinematic-MRI point-of-interest study. Int J Radiat Oncol Biol Phys (2007) 1.29
Intermixed normal tissue within prostate cancer: effect on MR imaging measurements of apparent diffusion coefficient and T2--sparse versus dense cancers. Radiology (2008) 1.28
Twenty-four-month postradiation prostate biopsies are strongly predictive of 7-year disease-free survival: results from a Canadian randomized trial. Cancer (2009) 1.26
PTEN losses exhibit heterogeneity in multifocal prostatic adenocarcinoma and are associated with higher Gleason grade. Mod Pathol (2012) 1.26
Association of tissue promoter methylation levels of APC, TGFβ2, HOXD3 and RASSF1A with prostate cancer progression. Int J Cancer (2011) 1.25
Focal laser ablation for prostate cancer followed by radical prostatectomy: validation of focal therapy and imaging accuracy. Eur Urol (2010) 1.25
Patient and community preferences for outcomes in prostate cancer: implications for clinical policy. Med Care (2003) 1.23
Suppression of hypoxia-inducible factor 2alpha restores p53 activity via Hdm2 and reverses chemoresistance of renal carcinoma cells. Cancer Res (2009) 1.18
Cancer detection and cancer characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC)--Section Rotterdam. A comparison of two rounds of screening. Eur Urol (2007) 1.18
Delay in surgical therapy for clinically localized prostate cancer and biochemical recurrence after radical prostatectomy. Can J Urol (2003) 1.17
Single nucleotide polymorphism of the human kallikrein-2 gene highly correlates with serum human kallikrein-2 levels and in combination enhances prostate cancer detection. J Clin Oncol (2003) 1.16
Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer: a large multi-institutional study. BJU Int (2010) 1.15
Sexual dysfunction after radical prostatectomy: prevalence, treatments, restricted use of treatments and distress. J Urol (2005) 1.14
PSA kinetics and PSA bounce following permanent seed prostate brachytherapy. Int J Radiat Oncol Biol Phys (2007) 1.13
Transperitoneal laparoscopic prostatectomy does not increase small bowel within the target volume for postoperative radiotherapy. J Urol (2009) 1.13
Evidence of multifocality of telomere erosion in high-grade prostatic intraepithelial neoplasia (HPIN) and concurrent carcinoma. Oncogene (2003) 1.11